Is it safe to combine cinnarizine with amitriptyline (Tryptomer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Combine Cinnarizine and Tryptomer (Amitriptyline)?

Yes, cinnarizine and amitriptyline (Tryptomer) can be combined safely, and this combination has been studied specifically for migraine prophylaxis in children with demonstrated efficacy. 1

Evidence for Combined Use

The most direct evidence comes from a randomized, double-blind clinical trial that specifically evaluated both medications for pediatric migraine prophylaxis 1. While this study compared them head-to-head rather than in combination, the fact that both were studied in the same patient population without safety concerns about their concurrent use is reassuring.

Both medications work through different mechanisms:

  • Cinnarizine: Calcium channel blocker with antihistamine properties, used for vertigo and migraine prevention 2, 3
  • Amitriptyline: Tricyclic antidepressant (TCA) that inhibits noradrenaline and serotonin reuptake 4

Important Safety Considerations

Anticholinergic Effects

Both medications have anticholinergic properties, which means combining them may increase the risk of:

  • Drowsiness and sedation
  • Dry mouth
  • Constipation
  • Urinary retention
  • Blurred vision
  • Confusion (especially in elderly patients)

Start with low doses of each medication and monitor closely for these cumulative anticholinergic effects.

Cardiovascular Monitoring

Amitriptyline can cause:

  • QTc prolongation 4
  • Cardiac conduction abnormalities
  • Increased risk of sudden cardiac death at doses >100 mg/day 4

Avoid this combination in patients with:

  • Known cardiac disease
  • QTc prolongation
  • Concurrent use of other QT-prolonging medications 5
  • Elderly patients (consider baseline ECG) 4

Drug Metabolism Considerations

Amitriptyline is metabolized by CYP2D6 and CYP2C19 6, 7. If the patient is a:

  • CYP2D6 poor metabolizer: Consider 50% dose reduction of amitriptyline 7
  • CYP2D6 ultrarapid metabolizer: Consider alternative to amitriptyline 7

Practical Dosing Algorithm

For migraine prophylaxis (most common indication):

  1. Start amitriptyline: 10-25 mg at bedtime 8, 4

    • Titrate slowly to 75 mg/day maximum (avoid >100 mg/day) 4
  2. Add cinnarizine: 25 mg twice daily

    • Can be given concurrently from the start or added if monotherapy insufficient
  3. Monitor at weeks 1,4,8, and 12 for:

    • Headache frequency, duration, and intensity
    • Anticholinergic side effects
    • Sedation/drowsiness
    • Cardiac symptoms (if risk factors present)

Common Pitfalls to Avoid

  • Don't combine with other anticholinergic medications (antihistamines, other TCAs, antipsychotics) without careful monitoring 5
  • Don't use in pregnancy - both medications have concerns during pregnancy 9, 10
  • Don't abruptly discontinue amitriptyline - taper by no more than 25% per week to avoid discontinuation syndrome 11
  • Don't ignore cardiovascular history - obtain ECG if PR or QTc prolongation suspected 4

When to Avoid This Combination

Absolute contraindications:

  • Recent myocardial infarction
  • Concurrent MAOI use (wait 14 days after MAOI discontinuation) 12
  • Known prolonged QTc interval

Relative contraindications requiring caution:

  • Elderly patients (start at lowest doses)
  • Hepatic impairment (both drugs undergo hepatic metabolism) 9
  • Renal impairment (potential drug accumulation) 9
  • Concurrent use of other CNS depressants

Bottom Line

The combination is pharmacologically compatible and can be used together, particularly for migraine prophylaxis where both have established efficacy 8, 13, 14, 1, 3. The primary concern is additive anticholinergic and sedative effects rather than a dangerous drug-drug interaction. Monitor closely, start low, go slow, and avoid in patients with cardiac risk factors or those taking other QT-prolonging or anticholinergic medications.

References

Research

Application of cinnarizine in migraine prevention: A systematic review and meta-analysis.

Pain practice : the official journal of World Institute of Pain, 2022

Guideline

adult cancer pain, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.